EUVIMEDEUVIMED entdecken
Open Access

Alternative splicing generates HER2 isoform diversity underlying antibody–drug conjugate resistance in breast cancer

Gabriela D A Guardia iD, Carlos H Dos Anjos iD, Aline Rangel-Pozzo iD, Filipe F Dos Santos iD, Alexander Birbrair iD, Paula F Asprino iD, Anamaria A Camargo iD, Pedro A F Galante iD

Genome Research · 2025

DOI: 10.1101/gr.280304.124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genome Research, 2025. Verfasst von Gabriela D A Guardia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Oncologia Molecular, Hospital Sírio Libanês, São Paulo 01308-050, Brazil. Hauptthemen laut MEDLINE: Alternative Splicing, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: São Paulo Research Foundation, Young Scientist program, Hospital Sírio-Libanês, CNPq.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BC) is a heterogeneous disease that can be molecularly classified based on the expression of the ERBB2 receptor (also known as HER2 ) and hormone receptors. Targeted therapies for HER2-positive BC, such as trastuzumab, antibody-drug conjugates (ADCs) and tyrosine kinase inhibitors, have improved patient outcomes, but primary/acquired resistance still poses challenges that can limit treatments’ long-term efficacy. Addressing these obstacles is vital for enhancing therapeutic strategies and patient care. Alternative splicing, a post-transcriptional mechanism that enhances transcript diversity (isoforms), can produce proteins with varied functions, cellular localizations, or binding properties. Here, we comprehensively characterize the HER2 alternative splicing isoforms, assess their expression in primary BC patients and cell lines, and explore their role in resistance to anti-HER2 therapies. We expand the catalog of known HER2 protein-coding isoforms from 13 to 90, revealing distinct patterns of protein domains, cellular localizations, and protein structures, along with their antibody-binding sites. By profiling expression in 561 primary BC samples and mass spectrometry data, we discover a complex landscape of HER2 isoform, revealing novel transcripts that were previously unrecognized and are not assessed in routine clinical practice. Finally, the assessment of HER2 isoform expression in BC cell cultures sensitive or resistant to trastuzumab and ADCs reveals that drug-resistant cells shift their expression toward isoforms lacking antibody-binding domains. Our results broaden the understanding of HER2 isoforms, revealing distinct mechanisms of potential resistance to anti-HER2 therapies, particularly ADCs. This expanded landscape of HER2 isoforms emphasizes the crucial role of alternative splicing investigations in advancing precision-targeted cancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alternative SplicingErb-b2 Receptor Tyrosine KinasesDrug Resistance, NeoplasmBreast NeoplasmsImmunoconjugatesHumansFemaleProtein IsoformsCell Line, TumorTrastuzumabGene Expression Regulation, Neoplastic

Substanzen

Erb-b2 Receptor Tyrosine KinasesProtein IsoformsImmunoconjugatesTrastuzumabERBB2 protein, human

Autor:innen und Institutionen

  • Centro de Oncologia Molecular, Hospital Sírio Libanês, São Paulo 01308-050, Brazil.
  • Department of Physiology and Pathophysiology, CancerCare Manitoba Research Institute, University of Manitoba, Winnipeg MB R3E 0J9, Canada.
  • Department de Bioquímica, Universidade de São Paulo, São Paulo 05508-000, Brazil.
  • Department of Dermatology, University of Wisconsin-Madison, Madison, Wisconsin 53715, USA.
  • Centro de Oncologia Molecular, Hospital Sírio Libanês, São Paulo 01308-050, Brazil; pgalante@mochsl.org.br.

ORCID-Profile: Gabriela D A Guardia, Carlos H Dos Anjos, Aline Rangel-Pozzo, Filipe F Dos Santos, Alexander Birbrair, Paula F Asprino, Anamaria A Camargo, Pedro A F Galante

Förderung

  • São Paulo Research Foundation
  • Young Scientist program, Hospital Sírio-Libanês
  • CNPq
  • Serrapilheira Foundation
  • Hospital Sírio-Libanês

Zitieren

APA

Guardia, G. D. A., Dos Anjos, C. H., Rangel-Pozzo, A., Dos Santos, F. F., Birbrair, A., Asprino, P. F., Camargo, A. A., & Galante, P. A. F. (2025). Alternative splicing generates HER2 isoform diversity underlying antibody–drug conjugate resistance in breast cancer. Genome Research. https://doi.org/10.1101/gr.280304.124

Vancouver

Guardia GDA, Dos Anjos CH, Rangel-Pozzo A, Dos Santos FF, Birbrair A, Asprino PF, et al. Alternative splicing generates HER2 isoform diversity underlying antibody–drug conjugate resistance in breast cancer. Genome Research. 2025. doi:10.1101/gr.280304.124

BibTeX
@article{Guardia2025,
  author = {Guardia, Gabriela D A and Dos Anjos, Carlos H and Rangel-Pozzo, Aline and Dos Santos, Filipe F and Birbrair, Alexander and Asprino, Paula F and Camargo, Anamaria A and Galante, Pedro A F},
  title = {Alternative splicing generates HER2 isoform diversity underlying antibody–drug conjugate resistance in breast cancer},
  journal = {Genome Research},
  year = {2025},
  doi = {10.1101/gr.280304.124}
}
Kostenlos starten →